Privileged structures: a useful concept for the rational design of new lead drug candidates.
about
Privileged scaffolds for library design and drug discoveryGetting in shape: controlling peptide bioactivity and bioavailability using conformational constraintsDiscovery of Novel Orally Active Tetrahydro-Naphthyl-N-Acylhydrazones with In Vivo Anti-TNF-α Effect and Remarkable Anti-Inflammatory PropertiesDiscovery of Leukotriene A4 Hydrolase Inhibitors Using Metabolomics Biased Fragment Crystallography †Leveraging structure determination with fragment screening for infectious disease drug targets: MECP synthase from Burkholderia pseudomalleiDiscovery of novel orally active anti-inflammatory N-phenylpyrazolyl-N-glycinyl-hydrazone derivatives that inhibit TNF-α production1,4-Thienodiazepine-2,5-diones via MCR (II): scaffold hopping by Gewald and Ugi-deprotection-cyclization strategyProbing chemical space with alkaloid-inspired libraries.Fragment screening of infectious disease targets in a structural genomics environmentAn integrated drug-likeness study for bicyclic privileged structures: from physicochemical properties to in vitro ADME properties.Recent trends and observations in the design of high-quality screening collections.Application of a sequential multicomponent assembly process/huisgen cycloaddition strategy to the preparation of libraries of 1,2,3-triazole-fused 1,4-benzodiazepines.The concept of privileged structures in rational drug design: focus on acridine and quinoline scaffolds in neurodegenerative and protozoan diseases.Expedient synthesis of norbenzomorphan library via multicomponent assembly process coupled with ring-closing reactionsSynthesis and diversification of 1,2,3-triazole-fused 1,4-benzodiazepine scaffoldsSynthesis and biological activities of the respiratory chain inhibitor aurachin D and new ring versus chain analoguesClustered patterns of species origins of nature-derived drugs and clues for future bioprospecting.Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery.Evaluation of the anti-Schistosoma mansoni activity of thiosemicarbazones and thiazolesTherapeutic target database update 2014: a resource for targeted therapeutics.Development of small-molecule therapies for autoimmune diseases.Novel HIV-1 non-nucleoside reverse transcriptase inhibitors: a patent review (2005 - 2010).Acylhydrazone derivatives: a patent review.Therapeutic potential of hydrazones as anti-inflammatory agents.Diverse Molecular Targets for Chalcones with Varied Bioactivities.Competitive binding of a benzimidazole to the histone-binding pocket of the Pygo PHD finger.A novel combinatorial biocatalytic approach for producing antibacterial compounds effective against Mycobacterium tuberculosis (TB).An overview of quinoline as a privileged scaffold in cancer drug discovery.Chalcone: A Privileged Structure in Medicinal Chemistry.In silico Prediction of Drug Induced Liver Toxicity Using Substructure Pattern Recognition Method.Identification of spirocyclic or phosphate substituted quinolizine derivatives as novel HIV-1 integrase inhibitors: a patent evaluation of WO2016094197A1, WO2016094198A1 and WO2016154527A1.Identification of Histamine H3 Receptor Ligands Using a New Crystal Structure Fragment-based Method.Multicomponent synthesis of diverse 1,4-benzodiazepine scaffolds.Synthesis, structure-affinity relationships, and modeling of AMDA analogs at 5-HT2A and H1 receptors: structural factors contributing to selectivity.Organocatalytic tandem Morita-Baylis-Hillman-Michael reaction for asymmetric synthesis of a drug-like oxa-spirocyclic indanone scaffold.GPCR Modulation of Thieno[2,3-b]pyridine Anti-Proliferative Agents.Discovery of naphthyl-N-acylhydrazone p38α MAPK inhibitors with in vivo anti-inflammatory and anti-TNF-α activity.Medium-Ring Nitrogen Heterocycles through Migratory Ring Expansion of Metalated Ureas.A domino reaction of 3-chlorochromones with aminoheterocycles. Synthesis of pyrazolopyridines and benzofuropyridines and their optical and ecto-5'-nucleotidase inhibitory effects.A highly efficient and eco-friendly method for the synthesis of 1,3-indandione ring-fused 3-oxindoles bearing two contiguous quaternary stereocenters via an aldol reaction in aqueous media.
P2860
Q24604575-E64106F7-24E5-4EF3-9265-46BF31719109Q27021652-1C6BB50C-953B-4693-BF6E-C2A70DAD5E23Q27343134-07FCC8F4-A868-406B-A714-7758E6A1E0D9Q27646546-4CC85896-ACB6-4D5E-A15F-F40C32324442Q27667103-03FA8718-FFAC-4FEC-ADFC-AB7D8C25E141Q28484258-C2729FCB-7EA2-4C87-96DC-1AEDC22A7737Q33603523-E4E49967-3EDB-48E8-9DC6-85C7AA2DCEACQ33626989-748F7A98-BFC2-43BB-8079-09D4A4B18ECCQ33836468-B349DF16-7B84-43A4-BD45-D4C1F953C7E3Q33888168-189E2F09-5C4E-49A9-9536-5C7BCE3816B3Q33893113-00A2928E-6942-410B-9012-1FAA6FA9039AQ34138274-4FB98B1F-4C9E-4C19-9680-C74FCB015026Q34286572-43367738-FE04-4069-AA9F-B2E201CF7F21Q34362791-D025FC4B-7747-4D8A-8DB3-921B8A2DB1DCQ34609448-19E7AC9D-2854-49DD-A617-41F8AB7719E0Q34942406-7F31666F-DA42-458E-A592-22A5E3A5282BQ35149474-82ABDD46-6E7D-45F2-9872-F8F05674235FQ35631111-4DDCA666-9543-451B-8998-6C0DD31C8780Q37544555-C76413E6-A299-4B1A-B949-69850217857BQ37661746-544D4A93-FC5B-4BA8-909E-E4C11A9DA138Q37730104-5EDB55C1-191D-4D85-8FB7-AC9EA6D25E77Q37860335-E596865A-71B7-4E8F-BAE4-E3F16C10E95CQ38248526-717B912D-EC7B-41DD-BBFD-5BD525D71A10Q38266479-21213F59-B6D8-44D9-AC0D-46C8AAE8F25AQ38707609-910EDE64-3B70-4F20-9227-E335F8973646Q39111904-F098CDD1-D5D6-4BD5-A598-72F46EFA5354Q39142098-516F2F33-0C24-45F3-B66C-30A708F4BC6BQ39235281-D8E8F9A9-F80F-4080-8F31-6ABC76B90409Q39295083-4B5068A7-72D4-4865-9495-5698FCD3EE31Q39523695-AC5A45DF-658D-4A52-9535-56DB5DC1ED1CQ40106207-4F810E6D-BC0E-48F8-A3EE-C01D9B156DB1Q40954666-1E32B8BF-0D85-42B4-9E9F-3F4EF01A15BEQ41816455-2C969254-0E34-43F2-B516-334159E4C5E1Q42727402-7CDC8D82-EA34-41A7-AE9A-C21178E69821Q43727709-0D6E0CE7-FA46-45AC-8B6E-8052E01D6439Q47274809-C45B07A2-6962-410D-86DA-CD3350A4FFB4Q47942159-178EF600-3FCA-4B77-9A3A-6BA7301179C9Q48149873-6E0097E0-E8EA-4F21-83BA-23B399C67CD3Q50179134-5F1CAC33-5897-49A1-AB06-CA91155DDEE5Q50446294-0122C904-DC98-4D42-BC5E-297949B1CDE0
P2860
Privileged structures: a useful concept for the rational design of new lead drug candidates.
description
2007 nî lūn-bûn
@nan
2007 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Privileged structures: a usefu ...... n of new lead drug candidates.
@ast
Privileged structures: a usefu ...... n of new lead drug candidates.
@en
Privileged structures: a usefu ...... n of new lead drug candidates.
@nl
type
label
Privileged structures: a usefu ...... n of new lead drug candidates.
@ast
Privileged structures: a usefu ...... n of new lead drug candidates.
@en
Privileged structures: a usefu ...... n of new lead drug candidates.
@nl
prefLabel
Privileged structures: a usefu ...... n of new lead drug candidates.
@ast
Privileged structures: a usefu ...... n of new lead drug candidates.
@en
Privileged structures: a usefu ...... n of new lead drug candidates.
@nl
P1476
Privileged structures: a usefu ...... n of new lead drug candidates.
@en
P2093
Carolina D Duarte
Eliezer J Barreiro
P304
P356
10.2174/138955707782331722
P50
P577
2007-11-01T00:00:00Z